ReviewJournal of virology2025
High seroprevalence and high risk: why are older adults more prone to respiratory syncytial virus?
Review in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Seasonal and Age-Stratified Patterns of Influenza, COVID-19, and RSV in Poland (2024-2026).Viruses · 2026Article
- An Appraisal of the Potential Downstream Benefits of RSV Vaccination in Older Adults.Reviews in medical virology · 2026Review
- Comparison of the Clinical Course of Viral Respiratory Infections in Hospitalized Patients During the 2025/2026 Season in Poland.Vaccines · 2026Article
- Delineating RSV-A and RSV-B: Epidemiological Patterns, Diagnostics, Clinical Severity, and Preventive Approaches.Journal of medical virology · 2026Review
- Article
- Kinetics of antibodies and risk of respiratory syncytial virus infection: a longitudinal cohort in Taizhou City, eastern China.BMC medicine · 2026Article
- Monitoring of RSV-A and RSV-B Circulation in Poland Across Three Post-Pandemic Seasons (2022-2025).Viruses · 2026Article
- Distinct Cytokine Landscapes Induced by Influenza a Virus, RSV, and SARS-CoV-2 in Older Adults (65+) Using an Ex Vivo Whole Blood Stimulation Model.Pathogens (Basel, Switzerland) · 2026Article
- Article
- Impact of previous SARS-CoV-2 infection on the severity of respiratory syncytial virus infection in hospitalized children.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Despite widespread seropositivity, respiratory syncytial virus (RSV) remains a major cause of severe illness in adults aged 60 years and older. This review examines why infection-acquired immunity fails to protect this group, focusing on four key factors: structural lung decline, comorbidities, immunosenescence, and impaired antibody responses. Age-related changes weaken mechanical defenses and antiviral immunity, while chronic diseases amplify RSV risk. Critically, repeated RSV infections may preferentially boost non-neutralizing antibodies targeting the postfusion F protein, limiting protection and possibly enhancing disease. The review also highlights how newly approved vaccines, based on stabilized prefusion F protein, can overcome these barriers by inducing strong neutralizing responses, offering a targeted strategy to reduce RSV burden in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.